insights_auto
Why is AXGN down 5,78%?
Dive Deeperchevron_right
AXGN:NASDAQ
AxoGen, Inc Common Stock
48,38 USD
arrow_downward
-5,78%(-2,97) 1D
5-ноя., 12:12:46 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
51,62 USD
High
51,85 USD
Low
48,30 USD
Mkt. cap
2,89 млд
Avg. vol.
1,78 млн
Volume
383,58 миң
52-wk high
52,91 USD
52-wk low
23,00 USD
EPS
-0,68 USD
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Open
51,62 USD
High
51,85 USD
Low
48,30 USD
Mkt. cap
2,89 млд
Avg. vol.
1,78 млн
Volume
383,58 миң
52-wk high
52,91 USD
52-wk low
23,00 USD
EPS
-0,68 USD
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
ABC News - Breaking News, Latest News and Videos
·
52 мүнөт мурун
Dow plunges 1,200 points, shedding most of midterm results stock rally
Axios
·
48 мүнөт мурун
Nasdaq plummets toward correction territory
The Block
·
20 мүнөт мурун
Canary's Injective ETF debuts on Nasdaq with exposure to staking rewards
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersАлачуа, Флорида, Америка Кошмо Штаттары
SectorMedical device
Industry-
Websiteaxogeninc.com